KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $255.7 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) fell 85.3% to $255.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $255.7 million, marking a year-over-year decrease of 85.3%. This contributed to the annual value of $255.7 million for FY2025, which is 85.3% down from last year.
  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $255.7 million in Q4 2025, which was down 85.3% from $256.4 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $259.4 million for Q1 2021, and its period low was $255.1 million during Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $257.7 million (2021), whereas its average is $257.4 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) crashed by 165.77% in 2022 and then soared by 90.16% in 2023.
  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $257.7 million in 2021, then decreased by 0.62% to $256.1 million in 2022, then rose by 0.62% to $257.7 million in 2023, then grew by 0.08% to $257.9 million in 2024, then dropped by 0.85% to $255.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $255.7 million for Q4 2025, versus $256.4 million for Q3 2025 and $256.8 million for Q2 2025.